Value added
Gilde Healthcare Partners is an expert in venture and growth capital in the healthcare sector. As experts, the team is able to identify (often at an early stage) promising investments and formulate value-creation strategies to help the companies realize their full potential. Gilde offers not only solid financial backing but also access to its extensive international network, highly experienced management team and operational partners.
Joël Jean-Mairet, former CEO GlycArt
“Working with Gilde during the last two years before GLYCART's successful exit was a great pleasure. They have a good understanding of business models that can make small companies successful. Besides cash Gilde Healthcare attracted co-investors and provided leadership and strategic guidance on our Board of Directors. If I were to start a biotech company again, I would go back to Gilde.”
Wick Goodspeed, CEO of FlowCardia, Inc.
“Gilde was the lead investor of our most significant financing round and became one of our largest and most active investors. I have found Gilde to be extremely supportive during the acquisition process by CR Bard. Their active role in strengthening and motivating management underlines their investment strategy focusing on people. It has been a pleasure to work with such a professional and experienced partner and Gilde would be the first European Healthcare investor that I would recommend to those planning for a financing round.”
Ian Nicholson, CEO Chroma Therapeutics
“Gilde invested in Chroma Therapeutics at an early stage in the development of the company and has participated in subsequent financings. The Gilde team and its advisers have a deep and broad knowledge of pharmaceutical research and development, which is of significant benefit to our company. We are delighted to have them as an active investor in Chroma.”
Edwin Moses, CEO Ablynx
“The rapid development of Ablynx has only been possible due to the direct support and encouragement of its investors. Gilde have been an investor in Ablynx since the early days. As an investor they have a broad knowledge and network within the life science sector but in addition they have specific and very valuable experience in the biologicals sector. I find the Gilde style to be one in which informed advice is offered freely but never imposed upon the company. I could not think of a better investor to work with.”
Kirsten Dreier, CEO Symphogen
“We are pleased with the recent investment by Gilde, a well-respected global private equity company experienced with European life science companies. Since their investment their excellent team has demonstrated commitment in sharing their in-depth knowledge of antibody technologies with us and contributed with valuable business input as well. We certainly got more than money from this investment”
Ronald HW Lorijn, CEO AMT
“Attracting the right VC group to invest into a gene therapy start-up company is more than just finding a financial sponsor. From the start Gilde has demonstrated and continues to be a real partner for AMT. While demonstrating their confidence in AMT’s management and corporate strategy Gilde Healthcare Partners using their know-how and extensive network contributes significantly to the growth of our company.”
Pieter Muntendam, CEO BG Medicine
“Gilde plays an important role in BG Medicine’s corporate development and its expansion into Europe. Gilde provided strong support in initiating and structuring the major alliance with Philips Research. This represents a key differentiator of this venture firm.”
Evert Küppers, CEO Pieris AG
“As one of the key investors, Gilde's presence on the Supervisory Board certainly played a role in deciding to join Pieris last year. Gilde clearly encompasses several important characteristics any CEO should look for in an investor: creative, pragmatic, reliable and stamina.”
Stephane Boissel, CFO Innate Pharma
“Gilde Healthcare Partners has been a loyal partner, willing to devote significant resources to Innate Pharma. Their commitment to us with capital as well as support with their growth network has made a difference in the development of our company. Gilde Healthcare Partners has been a key investor in our company which is underlined by their significant support in this IPO.”
Mark Vaeck, former CEO Ablynx
“I enjoyed working with Gilde during the several years I was CEO of Ablynx. As investors with a long-term vision and commitment, they displayed a very good understanding of the business and technology of Ablynx. They have an excellent team and appreciate that starting a company requires much more than cash, so they work closely with the founders to build successful organizations.”
